A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...

When the researchers had 132 patients with advanced melanoma or non-small cell lung cancer answer detailed diet history ...

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

Studies suggest that 15-20 per cent of lung cancer cases occur in people who have never smoked, mostly women. A World Lung Cancer Day special ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Imdelltra received accelerated approval from the U.S. Food and Drug Administration in May 2024 for patients with extensive-stage small cell lung cancer with disease progression on or after ...

The drug is being developed for the treatment of small cell lung cancer and neuroendocrine carcinoma, including neuroendocrine prostate cancer. The multi-center, first-in-human, open-label, phase 2/3 ...

They looked at blood samples from 41 patients with lung cancer (mostly non-small cell) treated with curative intent for stage I to III disease (mostly stage III). Median follow-up was 35 months.

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, ...